SRDX - Surmodics, Inc.

NasdaqGS - NasdaqGS Delayed Price. Currency in USD
31.45
+0.25 (+0.80%)
At close: 4:00PM EDT
Stock chart is not supported by your current browser
Previous Close31.20
Open31.73
Bid0.00 x 0
Ask0.00 x 0
Day's Range30.75 - 32.05
52 Week Range21.90 - 32.80
Volume49,801
Avg. Volume35,503
Market Cap412.31M
Beta0.54
PE Ratio (TTM)68.52
EPS (TTM)0.46
Earnings DateNov 14, 2017 - Nov 20, 2017
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est36.83
Trade prices are not sourced from all markets
  • Capital Cube13 days ago

    ETFs with exposure to SurModics, Inc. : October 6, 2017

    Categories: ETFs Yahoo FinanceClick here to see latest analysis ETFs with exposure to SurModics, Inc. Here are 5 ETFs with the largest exposure to SRDX-US. Comparing the performance and risk of SurModics, Inc. with the ETFs that have exposure to it gives us some ETF choices that could give us similar returns with lower volatility. Ticker Fund Name ... Read more (Read more...)

  • SurModics, Inc. :SRDX-US: Earnings Analysis: Q3, 2017 By the Numbers : October 5, 2017
    Capital Cube14 days ago

    SurModics, Inc. :SRDX-US: Earnings Analysis: Q3, 2017 By the Numbers : October 5, 2017

    Categories: Yahoo FinanceGet free summary analysis SurModics, Inc. reports financial results for the quarter ended June 30, 2017. We analyze the earnings along side the following peers of SurModics, Inc. – Enzo Biochem, Inc. and Agilent Technologies, Inc. (ENZ-US and A-US) that have also reported for this period. Highlights Summary numbers: Revenues of USD 17.79 million, Net ... Read more (Read more...)

  • Surmodics Receives FDA's Approval for PTA Balloon Catheter
    Zackslast month

    Surmodics Receives FDA's Approval for PTA Balloon Catheter

    Surmodics (SRDX) receives FDA's approval for PTA Balloon Catheter, which will boost its presence in the global peripheral artery disease market.

  • Thomson Reuters StreetEventslast month

    Edited Transcript of SRDX earnings conference call or presentation 3-Aug-17 12:30pm GMT

    Q3 2017 Surmodics Inc Earnings Call

  • Business Wirelast month

    Surmodics Announces Global Approvals of .014" Low-Profile PTA Balloon Dilation Catheter

    Surmodics, Inc. , a leading provider of medical device and in vitro diagnostic technologies to the healthcare industry, announced it has received U.S. Food and Drug Administration 510 and CE Mark clearance for its .014” low-profile percutaneous transluminal angioplasty balloon dilation catheter, designed for peripheral angioplasty procedures.

  • Surmodics Presents Encouraging SurVeil DCB Data at VIVA Meet
    Zackslast month

    Surmodics Presents Encouraging SurVeil DCB Data at VIVA Meet

    Surmodics' (SRDX) promising data on SurVeil DCB will boost its fortunes in the symptomatic peripheral artery disease space.

  • Business Wirelast month

    Six-Month Data from the Surmodics SurVeil® Drug-Coated Balloon Early Feasibility Study Presented at VIVA 2017

    Surmodics, Inc. , a leading provider of medical device and in vitro diagnostic technologies, today announced that data from the PREVEIL early feasibility study of the company’s SurVeil® drug-coated balloon was shared in a late-breaking clinical trial presentation at the Vascular Interventional Advances 2017 conference in Las Vegas.

  • SurModics, Inc. breached its 50 day moving average in a Bullish Manner : SRDX-US : September 5, 2017
    Capital Cubelast month

    SurModics, Inc. breached its 50 day moving average in a Bullish Manner : SRDX-US : September 5, 2017

    Categories: ETFs Yahoo FinanceGet full CapitalCube analysis *Disclaimer : This is as of previous day’s closing price. Technical Indicators Below is a quick look at 5 technical indicators for SurModics, Inc.. More studies are available on the Technical Chart. Indicator Signal Closing Price above/below 50 Day Moving Average Bullish Closing Price above/below 200 Day Moving Average Bullish 50 ... Read more (Read more...)

  • SurModics, Inc. – Value Analysis (NASDAQ:SRDX) : August 15, 2017
    Capital Cube2 months ago

    SurModics, Inc. – Value Analysis (NASDAQ:SRDX) : August 15, 2017

    Categories: Fundamental Analysis Yahoo FinanceClick here to see latest analysis Capitalcube gives SurModics, Inc. a score of 81. Our analysis is based on comparing SurModics, Inc. with the following peers – Nektar Therapeutics, Thermo Fisher Scientific Inc., Heron Therapeutics Inc, Abbott Laboratories, pSivida Corp., Johnson & Johnson, PerkinElmer, Inc., Enzo Biochem, Inc., Alkermes Plc and Agilent Technologies, Inc. (NKTR-US, ... Read more (Read more...)

  • Surmodics (SRDX) Beats Earnings & Revenue Estimates in Q3
    Zacks2 months ago

    Surmodics (SRDX) Beats Earnings & Revenue Estimates in Q3

    Surmodics (SRDX) received IDE approval from the FDA for its TRANSCEND SurVeil DCB pivotal study in the third quarter. An upbeat guidance raises investor confidence.

  • Associated Press3 months ago

    SurModics posts 3Q profit

    The Eden Prairie, Minnesota-based company said it had net income of 5 cents per share. Earnings, adjusted for one-time gains and costs, were 9 cents per share. The drug delivery technology company posted ...

  • Business Wire3 months ago

    Surmodics Reports Third Quarter Fiscal 2017 Results and Updates Fiscal 2017 Guidance

    Surmodics, Inc. , a leading provider of medical device and in vitro diagnostic technologies to the healthcare industry, today announced results for its fiscal 2017 third quarter, ended June 30, 2017.

  • SurModics, Inc. breached its 50 day moving average in a Bearish Manner : SRDX-US : August 2, 2017
    Capital Cube3 months ago

    SurModics, Inc. breached its 50 day moving average in a Bearish Manner : SRDX-US : August 2, 2017

    Categories: ETFs Yahoo FinanceGet full CapitalCube analysis *Disclaimer : This is as of previous day’s closing price. Technical Indicators Below is a quick look at 5 technical indicators for SurModics, Inc.. More studies are available on the Technical Chart. Indicator Signal Closing Price above/below 50 Day Moving Average Bearish Closing Price above/below 200 Day Moving Average Bullish 50 ... Read more (Read more...)

  • Business Wire3 months ago

    Surmodics Receives IDE Approval to Initiate Pivotal Trial of the SurVeil™ Drug-Coated Balloon

    Surmodics, Inc. , a leading provider of medical device and in vitro diagnostic technologies, today announced it has received an investigational device exemption from the U.S.

  • Business Wire3 months ago

    Surmodics to Webcast Third Quarter 2017 Earnings Conference Call on August 3

    Surmodics, Inc. , a leading provider of medical device and in vitro diagnostic technologies to the healthcare industry, today announced that it will host a live webcast of its third quarter fiscal 2017 conference call on Thursday, August 3, at 7:30 a.m.

  • SurModics, Inc. breached its 50 day moving average in a Bullish Manner : SRDX-US : May 29, 2017
    Capital Cube5 months ago

    SurModics, Inc. breached its 50 day moving average in a Bullish Manner : SRDX-US : May 29, 2017

    Categories: ETFs Yahoo FinanceClick here to see latest analysis *Disclaimer : This is as of previous day’s closing price. Technical Indicators Below is a quick look at 5 technical indicators for SurModics, Inc.. More studies are available on the Technical Chart. Indicator Signal Closing Price above/below 50 Day Moving Average Bullish Closing Price above/below 200 Day Moving Average ... Read more (Read more...)

  • Business Wire5 months ago

    Surmodics to Present at Upcoming Investor Conferences

    Surmodics, Inc. , a leading provider of medical device and in vitro diagnostic technologies to the healthcare industry, today announced that Gary Maharaj, president and chief executive officer, and Andy LaFrence, vice president of finance and information systems and chief financial officer, will be attending two upcoming investor conferences.

  • Capital Cube5 months ago

    ETFs with exposure to SurModics, Inc. : May 5, 2017

    Categories: ETFs Yahoo FinanceClick here to see latest analysis ETFs with exposure to SurModics, Inc. Here are 5 ETFs with the largest exposure to SRDX-US. Comparing the performance and risk of SurModics, Inc. with the ETFs that have exposure to it gives us some ETF choices that could give us similar returns with lower volatility. Ticker Fund Name ... Read more (Read more...)

  • SurModics, Inc. :SRDX-US: Earnings Analysis: Q2, 2017 By the Numbers : May 3, 2017
    Capital Cube6 months ago

    SurModics, Inc. :SRDX-US: Earnings Analysis: Q2, 2017 By the Numbers : May 3, 2017

    Categories: Yahoo FinanceGet free summary analysis SurModics, Inc. reports financial results for the quarter ended March 31, 2017. We analyze the earnings along side the following peers of SurModics, Inc. – Thermo Fisher Scientific Inc., Abbott Laboratories, Johnson & Johnson and Alkermes Plc (TMO-US, ABT-US, JNJ-US and ALKS-US) that have also reported for this period. Highlights Summary ... Read more (Read more...)

  • Thomson Reuters StreetEvents6 months ago

    Edited Transcript of SRDX earnings conference call or presentation 27-Apr-17 12:30pm GMT

    Q2 2017 Surmodics Inc Earnings Call

  • SurModics, Inc. breached its 50 day moving average in a Bearish Manner : SRDX-US : April 28, 2017
    Capital Cube6 months ago

    SurModics, Inc. breached its 50 day moving average in a Bearish Manner : SRDX-US : April 28, 2017

    Categories: ETFs Yahoo FinanceClick here to see latest analysis *Disclaimer : This is as of previous day’s closing price. Technical Indicators Below is a quick look at 5 technical indicators for SurModics, Inc.. More studies are available on the Technical Chart. Indicator Signal Closing Price above/below 50 Day Moving Average Bearish Closing Price above/below 200 Day Moving Average ... Read more (Read more...)

  • Associated Press6 months ago

    SurModics posts 2Q profit

    The Eden Prairie, Minnesota-based company said it had profit of 4 cents per share. Earnings, adjusted for one-time gains and costs, came to 5 cents per share. The drug delivery technology company posted ...

  • Business Wire6 months ago

    Surmodics Reports Second Quarter Fiscal 2017 Results, Updates Fiscal 2017 Financial Guidance

    Surmodics, Inc. , a leading provider of medical device and in vitro diagnostic technologies to the healthcare industry, today announced results for its fiscal 2017 second quarter, ended March 31, 2017.

  • Capital Cube6 months ago

    SurModics, Inc. – Value Analysis (NASDAQ:SRDX) : April 19, 2017

    Categories: Fundamental Analysis Yahoo FinanceClick here to see latest analysis Capitalcube gives SurModics, Inc. a score of 81. Our analysis is based on comparing SurModics, Inc. with the following peers – Nektar Therapeutics, Thermo Fisher Scientific Inc., Heron Therapeutics Inc, Abbott Laboratories, pSivida Corp., Johnson & Johnson, PerkinElmer, Inc., Enzo Biochem, Inc., Alkermes Plc and Agilent Technologies, Inc. (NKTR-US, ... Read more (Read more...)

  • Capital Cube6 months ago

    SurModics, Inc. breached its 50 day moving average in a Bullish Manner : SRDX-US : April 18, 2017

    Categories: ETFs Yahoo FinanceClick here to see latest analysis *Disclaimer : This is as of previous day’s closing price. Technical Indicators Below is a quick look at 5 technical indicators for SurModics, Inc.. More studies are available on the Technical Chart. Indicator Signal Closing Price above/below 50 Day Moving Average Bullish Closing Price above/below 200 Day Moving Average ... Read more (Read more...)